Serum Amyloid A in Stable COPD Patients is Associated with the Frequent Exacerbator Phenotype

References

• CelliBR, BarnesPJ. Exacerbations of chronic obstructive pulmonary disease. European Respir J. 2007;29(6):1224–1238. doi:10.1183/09031936.0010990617540785
   PubMed Web of Science ®Google Scholar
• PatelIS, SeemungalTAR, WilksM, Lloyd-OwenSJ, DonaldsonGC, WedzichaJA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759–764. doi:10.1136/thorax.57.9.75912200518
   PubMed Web of Science ®Google Scholar
• SeemungalTAR, DonaldsonGC, PaulEA, BestallJC, JeffriesDJ, WedzichaJA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418–1422. doi:10.1164/ajrccm.157.5.97090329603117
   PubMed Web of Science ®Google Scholar
• SeneffMG, WagnerDP, WagnerRP, ZimmermanJE, KnausWA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995;274(23):1852–1857. doi:10.1001/jama.1995.035302300380277500534
   PubMed Web of Science ®Google Scholar
• WedzichaJA, RabeKF, MartinezFJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143(5):1302–1311. doi:10.1378/chest.12-148923117188
   PubMed Web of Science ®Google Scholar
• SethiS, WronaC, EschbergerK, LobbinsP, CaiX, MurphyTF. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(5):491–497. doi:10.1164/rccm.200708-1234OC18079493
   PubMed Web of Science ®Google Scholar
• GompertzS, O’BrienC, BayleyDL, HillSL, StockleyRA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. European Respir J. 2001;17(6):1112–1119. doi:10.1183/09031936.01.9911490111491152
   PubMed Web of Science ®Google Scholar
• CrooksSW, BayleyDL, HillSL, StockleyRA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. European Respir J. 2000;15(2):274–280. doi:10.1034/j.1399-3003.2000.15b09.x10706491
   PubMed Web of Science ®Google Scholar
• WedzichaJA, SeemungalTAR, MacCallumPK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84(08):210–215. doi:10.1055/s-0037-161399810959691
   PubMed Web of Science ®Google Scholar
• DevD, WallaceE, SankaranR, CunniffeJ, EmmanuelFXS. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med. 1998;92(4):664–667. doi:10.1016/S0954-6111(98)90515-79659534
   PubMed Web of Science ®Google Scholar
• BhowmikA, SeemungalTA, SapsfordRJ, WedzichaJA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114. doi:10.1136/thorax.55.2.11410639527
   PubMed Web of Science ®Google Scholar
• PereraWR, HurstJR, WilkinsonTMA, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. European Respir J. 2007;29(3):527. doi:10.1183/09031936.0009250617107990
   PubMed Web of Science ®Google Scholar
• HurstJR, DonaldsonGC, PereraWR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867–874. doi:10.1164/rccm.200604-506OC16799074
   PubMed Web of Science ®Google Scholar
• BozinovskiS, HutchinsonA, ThompsonM, et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(3):269–278. doi:10.1164/rccm.200705-678OC18006888
   PubMed Web of Science ®Google Scholar
• UhlarCM, WhiteheadAS. Serum amyloid A, the major vertebrate acute‐phase reactant. European j Biochem. 1999;265(2):501–523. doi:10.1046/j.1432-1327.1999.00657.x10504381
   PubMedGoogle Scholar
• Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2020 Report. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://www.goldcopd.org. Accessed 92, 2020.
   Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• PellegrinoR, ViegiG, BrusascoV, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968. doi:10.1183/09031936.05.0003520516264058
   PubMed Web of Science ®Google Scholar
• ZhengJ, ZhongN. Normative values of pulmonary function testing in Chinese adults. Chin Med J. 2002;115(1):50–54.11930658
   PubMed Web of Science ®Google Scholar
• ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171(8):912–930. doi:10.1164/rccm.200406-710ST15817806
   PubMed Web of Science ®Google Scholar
• GulatiS, WellsJM, UrdanetaGP, et al. Fibroblast growth factor 23 is associated with a frequent Exacerbator phenotype in COPD: a cross-sectional pilot study. Int J Mol Sci. 2019;20(9):2292. doi:10.3390/ijms20092292
   PubMed Web of Science ®Google Scholar
• VietriL, BennettD, CameliP, et al. Serum amyloid A in patients with idiopathic pulmonary fibrosis. Respir Investig. 2019;57(5):430–434. doi:10.1016/j.resinv.2019.03.010
   PubMed Web of Science ®Google Scholar
• FormigaMF, VitalI, UrdanetaG, et al. Higher serum levels of systemic inflammatory markers are linked to greater inspiratory muscle dysfunction in COPD. Clin Respir J. 2019;13(4):247–255. doi:10.1111/crj.1300630773817
   PubMed Web of Science ®Google Scholar
• LinTL, ChenWW, DingZR, WeiSC, HuangML, LiCH. Correlations between serum amyloid A, C-reactive protein and clinical indices of patients with acutely exacerbated chronic obstructive pulmonary disease. J Clin Lab Anal. 2019;33(4):e22831. doi:10.1002/jcla.2283130666727
   PubMed Web of Science ®Google Scholar
• JohnsonBD, KipKE, MarroquinOC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the national heart, lung, and blood institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109(6):726–732. doi:10.1161/01.CIR.0000115516.54550.B114970107
   PubMed Web of Science ®Google Scholar
• SinDD, ManSF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. doi:10.1161/01.CIR.0000056767.69054.B312654609
   PubMed Web of Science ®Google Scholar
• Rodriguez-RoisinR. Is this the beginning of unravelling the puzzle of COPD exacerbations? Eur Respir J. 2005;26(3):376–378. doi:10.1183/09031936.05.0007620516135715
   PubMed Web of Science ®Google Scholar
• AnthonyD, SeowHJ, UddinM, et al. Serum amyloid A promotes lung neutrophilia by increasing IL-17A levels in the mucosa and gammadelta T cells. Am J Respir Crit Care Med. 2013;188(2):179–186. doi:10.1164/rccm.201211-2139OC23627303
   PubMed Web of Science ®Google Scholar
• AtherJL, CklessK, MartinR, et al. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol. 2011;187(1):64–73. doi:10.4049/jimmunol.110050021622869
   PubMed Web of Science ®Google Scholar
• MengQR, GideonKM, HarboSJ, et al. Gene expression profiling in lung tissues from mice exposed to cigarette smoke, lipopolysaccharide, or smoke plus lipopolysaccharide by inhalation. Inhal Toxicol. 2006;18(8):555–568. doi:10.1080/0895837060068622616717027
   PubMed Web of Science ®Google Scholar
• MerkelD, RistW, SeitherP, WeithA, LenterMC. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics. 2005;5(11):2972–2980. doi:10.1002/pmic.20040118016075419
   PubMed Web of Science ®Google Scholar
• VoorhoutWF, VeenendaalT, KurokiY, OgasawaraY, van GoldeLM, GeuzeHJ. Immunocytochemical localization of surfactant protein D (SP-D) in type II cells, Clara cells, and alveolar macrophages of rat lung. J Histochem Cytochem. 1992;40(10):1589–1597. doi:10.1177/40.10.15273771527377
   PubMed Web of Science ®Google Scholar
• FisherJH, SheftelyevichV, HoYS, et al. Pulmonary-specific expression of SP-D corrects pulmonary lipid accumulation in SP-D gene-targeted mice. Am J Physiol Lung Cell Mol Physiol. 2000;278(2):L365–373. doi:10.1152/ajplung.2000.278.2.L36510666121
   PubMed Web of Science ®Google Scholar
• SinDD, PahlavanPS, ManSFP. Surfactant protein D: a lung specific biomarker in COPD? Ther Adv Respir Dis. 2008;2(2):65–74. doi:10.1177/175346580808890319124360
   PubMedGoogle Scholar
• WrightJR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5(1):58–68. doi:10.1038/nri152815630429
   PubMed Web of Science ®Google Scholar
• ObeidatM, LiX, BurgessS, et al. Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. European Respir J. 2017;50(5):1700657. doi:10.1183/13993003.00657-201729191953
   PubMed Web of Science ®Google Scholar
• WertSE, YoshidaM, LeVineAM, et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci U S A. 2000;97(11):5972–5977. doi:10.1073/pnas.10044899710801980
   PubMed Web of Science ®Google Scholar
• SørensenGL, HjelmborgJVB, KyvikKO, FengerM, HolmskovU. Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol. 2006;290(5):L1010–1017. doi:10.1152/ajplung.00487.200516361352
   PubMed Web of Science ®Google Scholar
• AtochinaEN, GowAJ, BeckJM, et al. Delayed clearance of Pneumocystis carinii infection, increased inflammation, and altered nitric oxide metabolism in lungs of surfactant protein-D knockout mice. J Infect Dis. 2004;189(8):1528–1539.15073692
   PubMed Web of Science ®Google Scholar
• LeVineAM, WhitsettJA, HartshornKL, CrouchEC, KorfhagenTR. Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol. 2001;167(10):5868–5873. doi:10.4049/jimmunol.167.10.586811698462
   PubMed Web of Science ®Google Scholar
• LeVineAM, ElliottJ, WhitsettJA, et al. Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol. 2004;31(2):193–199. doi:10.1165/rcmb.2003-0107OC15016617
   PubMed Web of Science ®Google Scholar
• WuH, KuzmenkoA, WanS, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest. 2003;111(10):1589–1602. doi:10.1172/JCI1688912750409
   PubMed Web of Science ®Google Scholar
• LomasDA, SilvermanEK, EdwardsLD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 2009;34(1):95–102. doi:10.1183/09031936.0015650819164344
   PubMed Web of Science ®Google Scholar
• van OosterhoutAJ, MottaAC. Th1/Th2 paradigm: not seeing the forest for the trees? Eur Respir J. 2005;25(4):591–593. doi:10.1183/09031936.05.0001410515802329
   PubMed Web of Science ®Google Scholar
• WeiB, ShengLC. Changes in Th1/Th2-producing cytokines during acute exacerbation chronic obstructive pulmonary disease. J Int Med Res. 2018;46(9):3890–3902. doi:10.1177/030006051878164229950127
   PubMed Web of Science ®Google Scholar
• HaoY, KuangZ, JingJ, et al. Mycoplasma pneumoniae modulates STAT3-STAT6/EGFR-FOXA2 signaling to induce overexpression of airway mucins. Infect Immun. 2014;82(12):5246–5255. doi:10.1128/IAI.01989-1425287927
   PubMed Web of Science ®Google Scholar